Table 4.
Rates of ARIA observed in Phase 3 trials of anti-amyloid monoclonal antibodies. Each trial had different entry criteria that may have affected the ARIA rates, and the figures are not directly comparable.
| Aducanumab (EMERGE) | Aducanumab (ENGAGE) | Lecanemab (Clarity) | Donanemab (Trailblazer-ALZ2) | |
|---|---|---|---|---|
| ARIA-E placebo | 2 | 3 | 1.7 | 1.9 |
| ARIA-E Tx; symptomatic | 20 | 29 | 2.8 | 6.1 |
| ARIA-E Tx; APOE non-carriers | 18 | 23 | 5.4 | 15.7 |
| ARIA-E Tx; APOE carriers | 43 | 42 | 15.8 | NA |
| ARIA-E Tx; APOE heterozygotes | NA | NA | 10.9 | 22.8 |
| ARIA-E Tx; APOE homozygotes | 65 | 65 | 32.6 | 40.6 |
| ARIA-H placebo; microhemorrhage | 7 | 6 | 7.6 | 12.5 |
| ARIA-H placebo; siderosis | 3 | 2 | 2.3 | 3.0 |
| ARIA-H Tx; microhemorrhage | 20 | 19 | 14.0 | 26.8 |
| ARIA-H Tx; siderosis | 13 | 16 | 5.6 | 15.7 |
∗Aducanumab percentages are from the high dose arms of the EMERGE and ENGAGE trials; NA - not available; Tx – active therapy.